Matrifen (Fentanyl)

Fentanyl is an opioid analgesic used for managing severe pain conditions.

• Severe chronic non‑cancer pain: provides continuous opioid delivery to maintain consistent analgesia.
• Cancer‑related pain: offers sustained relief for patients with advanced malignancies.
• Breakthrough pain (as adjunct to other opioid therapy): supplements baseline analgesia during episodic pain spikes.

• Fentanyl binds with high affinity to the μ‑opioid receptors in the central nervous system, inhibiting the release of neurotransmitters involved in pain transmission. This receptor activation reduces neuronal excitability and alters the perception of pain, producing potent analgesic effects while also influencing respiratory and gastrointestinal pathways.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Constipation: reduced bowel motility.
• Drowsiness: increased sleepiness.
• Dizziness: sensation of light‑headedness.
• Sweating: excessive perspiration at the application site.
• Application site reactions: redness or itching where the patch is placed.

Serious or Rare Side Effects

• Respiratory depression: dangerously slowed breathing.
• Severe hypotension: marked drop in blood pressure.
• Adrenal insufficiency: impaired cortisol production.
• Skin necrosis: tissue death at the patch site.
• Opioid dependence or abuse: risk of addiction.
• Anaphylaxis: life‑threatening allergic reaction.

Before prescribing Matrifen, clinicians should consider several safety measures.

• Assess pain severity and opioid tolerance: ensure the patient requires continuous opioid therapy.
• Evaluate respiratory function: avoid use in patients with significant respiratory depression.
• Review hepatic and renal function: dose adjustments may be needed in impairment.
• Monitor for signs of addiction or misuse: implement appropriate risk mitigation.
• Counsel on proper application: rotate patch sites to minimize skin irritation.
• Store at room temperature: keep patch in original packaging, protect from moisture and direct sunlight.

Fentanyl may interact with other medications, requiring careful management.

Major Interactions (Avoid)

• Respiratory depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression.
• MAO inhibitors: may cause severe hypotension and serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase fentanyl plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce fentanyl effectiveness.
• Other CNS depressants (e.g., alcohol, antihistamines): may enhance sedation and dizziness.